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To all patients with SSc with the hope that this Thesis will spread 
some new knowledge, insights and, maybe, help. 
///H
ABSTRACT
Background and aims: Systemic sclerosis (SSc) is a multisystem rheumatic 
disease characterized by fibrosis, vasculopathy and immune system activation. 
There is a dearth of knowledge how different subphenotypes such as patients 
with no–mild and moderate–end-stage lung disease differs in physical function 
and activity, muscle function and active range of motion. Likewise, no study has 
yet investigated what experiences patients with SSc have of physical activity and 
 exercise. Although it is known that many patients with SSc have physical disabili-
ties, reduced health-related quality of life (HRQoL) and have anxiety and depres-
sion symptoms, little is known about differences between patients with no–mild 
and moderate–end-stage lung disease respectively. The overarching aim of this 
Thesis was to increase the knowledge of physical function, physical activity and 
HRQoL in patients with SSc and different degrees of lung disease. The specific 
aims were to investigate the differences in physical capacity, physical activity, 
muscle  function and range of motion in comparison with population-based controls 
or reference  values. Further, a specific aim was to explore patients’ own experi-
ences of physical activity and exercise.
Participants and methods: Three Cross-sectional studies were performed. In 
paper 1, 106 patients with SSc and 106 age- and gender-matched population-
based controls were involved. In paper II, 205 patients with SSc were compared 
with reference values and in a paper III, 279 patients were involved. Further, a 
qualitative study with interviews of 16 individuals with SSc were performed and 
underwent a content analysis. 
Results: Paper I: Patients with SSc reported overall lower physical capacity for 
walking, jogging, and running, and more limiting factors for physical capacity than 
controls. Patients with no–mild lung disease reported pain more often than their 
controls, whereas moderate–severe lung disease patients reported  cardiopulmonary 
disease and reduced muscle strength as limiting factors for physical capacity more 
often than their controls. More patients than controls had ‘never exercised’ for at 
least 30 min per occasion within the past year; however, there were no differences 
overall between patients and controls in frequency of  exercise, physical activity, 
nor time spent sitting. Paper II: Shoulder- and hip flexion muscle endurance 
were lower in relation to reference values, median [53% and 40% of predicted], 
respectively. Patients with moderate–end-stage lung disease had lower endur-
ance in shoulder- and hip flexion [39% and 35%] than patients with no-mild lung 
disease [57% and 48%]. All patients, regardless subtype/grouping, needed longer 
time to complete the Timed-Stands Test (TST) [21 s] compared to reference values 
[17 s], and patients with moderate–end-stage lung disease needed longer time to 
complete TST than patients with no-mild lung involvement, [25 s vs 19 s]. Active 
range of motion in shoulder-arm were lower compared with reference values, 
and patients with dcSSc had lower shoulder-arm movement than patients with 
lcSSc. Paper III: The following three themes (and categories) emerged from the 
analysis: Essential for life and health (Diminishes symptoms and is as effective as 
pharmaceuticals, Reduces fear of deterioration, and, Feeling healthy and satisfied 
with oneself); Disease-related and other hindrances (Breathlessness, pain and other 
disease consequences limit, Risk of worsening, and, Non-disease barriers); and, 
Own understanding about physical activity/exercise and support from healthcare 
(Experience-based knowledge about own capability and physical activity/exercise, 
and, Education and support from healthcare and others). Paper IV: Patients with 
moderate–end-stage lung disease scored lower on Medical Outcomes Trust Short 
Form 36 (SF-36) physical component score than no–mild. Patients with  moderate–
end-stage lung disease had lower physical capacity, were less physical active on 
low-moderate intensity and exercised less the past year compared with no–mild. 
Patients with moderate–end-stage lung disease scored higher on Health Assessment 
Questionnaire (HAQ) and higher scores on Hospital Anxiety Depression scale 
(HADs), than the no–mild group. In the whole SSc sample, the SF-36 physical 
component score correlated highly with HAQ and moderately with symptoms on 
HAQ-VAS- general, dyspnoea, pain; and physical capacity, while SF-36 mental 
component score correlated moderately with anxiety and depression (HAD).
Conclusions: Although SSc patients reported lower physical capacity and more 
limiting factors for physical capacity than controls, there were no differences in 
reported physical activity and time spent sitting. However, SSc patients have mark-
edly reduced muscle endurance in both the upper and lower extremities, reduced 
muscle strength in the lower extremities and impaired active range of motion 
in the shoulders and arms. Patients with moderate-end stage lung involvement 
had more impaired muscle endurance and strength than those with no-mild lung 
involvement but surprisingly no differences were found between lcSSc and dcSSc 
patients. Among individuals with SSc with both no-mild and moderate–end-stage 
lung disease, physical activity and exercise was expressed as essential for life and 
health and that it reduces fear of deterioration. Nevertheless, it was also expressed 
as a risk for worsening. As patients with SSc with moderate-severe lung disease 
have lower physical capacity, are less physically active and exercise less, are more 
physically disabled, have a lower physical HRQoL and have more depressive symp-
toms than patients with no-mild lung disease, individualized physical activity and 
exercise support from physiotherapist might be beneficial. The studies included 
in this thesis contributes to new knowledge, about how to develop and evaluate 
future physical exercise programs including resistance training for patients with 
SSc, especially for those with more severe lung disease. 
SVENSK SAMMANFATTNING
Bakgrund och syften: Systemisk skleros (SSc) är en reumatisk multisystem-
sjukdom som karaktäriseras av fibros, vaskulopati och immunsystemsaktivering. 
Det råder brist på kunskap hur olika subtyper, som patienter med ingen–mild och 
måttlig–mycket svår lungsjukdom, skiljer sig i fysisk kapacitet och fysisk aktivi-
tet, muskelfunktion och aktivt rörelseomfång. Dessutom finns ingen studie som 
undersökt vilka erfarenheter patienter med SSc har av fysisk aktivitet och träning. 
Även om det är känt att patienter med SSc har fysiska funktionsnedsättningar, 
nedsatt hälsorelaterad livskvalitet (HRQoL) och problem med ångest och depres-
sion, är lite känt om eventuella skillnader mellan patienter med ingen–mild och 
måttlig–mycket svår lungsjukdom. Det övergripande syftet med denna avhandling 
var att öka kunskapen om fysisk funktion, fysisk aktivitet och HRQoL hos patienter 
med SSc och olika grad av lungsjukdom. De specifika syftena var att undersöka 
skillnader i fysisk kapacitet, fysisk aktivitet, muskelfunktion och rörelseomfång i 
jämförelse med befolkningsbaserade kontroller eller referensvärden. Ytterligare 
ett specifikt mål var att utforska patienternas egna erfarenheter av fysisk aktivitet 
och träning. 
Deltagare och metoder: Tre tvärsnittsstudier utfördes. I delarbete 1 inkluderades 
106 patienter med SSc och 106 ålders- och könsmatchade kontrollpersoner. I del-
arbete II jämfördes 205 patienter med SSc med referensvärden och i delarbete III 
var 279 patienter inkluderade. Vidare utfördes en kvalitativ studie med individuella 
intervjuer av 16 personer med SSc där intervjuerna genomgick en innehållsanalys.
Resultat: Delarbete I: Patienter med SSc rapporterade överlag en lägre fysisk 
förmåga att gå, jogga och springa, och fler begränsande faktorer för fysisk kapa-
citet än kontrollpersonerna. Patienter med ingen–mild lungsjukdom rapporterade 
smärta oftare än deras kontroller, medan patienter med måttlig–svår lungsjukdom 
rapporterade hjärt-kärlsjukdomar och minskad muskelstyrka som begränsande 
faktorer för fysisk kapacitet oftare än deras kontroller. Fler patienter än kontrol-
ler hade ”aldrig tränat” i minst 30 minuter per tillfälle under det senaste året. Det 
fanns emellertid inga skillnader mellan patienterna och kontrollerna avseende 
frekvensen av träning, fysisk aktivitet eller stillasittande under dagen. Delarbete 
II: Muskeluthålligheten i axel- och höftflexion var lägre än referensvärden, 
median [53% respektive 40% av förväntade]. Patienter med måttlig–mycket svår 
lungsjukdom hade lägre uthållighet i axel- och höftflektion [39% och 35%] än 
patienter med ingen–mild lungsjukdom [57% och 48%]. Alla patienter, oavsett 
subtyp/gruppering, behövde längre tid för att slutföra Timed-Stands Test [21 s] 
jämfört med referensvärden [17 s], och patienter med måttlig–mycket svår lung-
sjukdom behövde längre tid för att slutföra testet än patienter med ingen–mild 
lungsjukdom [25 s vs 19 s]. Aktivt rörelseomfång i skuldra-arm var mindre jämfört 
med referensvärden, och patienter med dcSSc hade mindre skuldra-armrörlighet 
än patienter med lcSSc. Delarbete III: Följande tre teman (och kategorier) 
framkom av analysen om fysisk aktivitet och träning: Viktigt för liv och hälsa 
(Minskar symtomen och är lika effektiv som läkemedel, Minskar rädsla för för-
sämring, och, Känner sig frisk och nöjd med sig själv); Sjukdomsrelaterade och 
andra hinder (Andfåddhet, smärta och andra sjukdomskonsekvenser begränsar, 
Risk för försämring, och, Icke-sjukdomsrelaterade hinder); och Egen förståelse 
för fysisk aktivitet/träning och stöd från vården (Erfarenhetsbaserad kunskap om 
egen förmåga och fysisk aktivitet/träning, och, Information och stöd från vården 
och andra). Delarbete IV: Patienter med måttlig–mycket svår lungsjukdom hade 
lägre värden på SF-36 PCS än de med ingen–mild lungsjukdom. Patienter med 
måttlig–mycket svår lungsjukdom hade lägre fysisk kapacitet, var mindre fysiskt 
aktiva på låg–måttlig intensitet samt hade tränat mindre det senaste året jämfört 
med patienter med ingen–mild lungsjukdom. Patienter med måttlig–mycket svår 
lungsjukdom hade sämre resultat på Funktionsskattningsformuläret (HAQ) och 
högre poäng på Hospital Anxiety Depression Scale (HAD) än de med ingen–mild 
lungsjukdom. I hela gruppen korrelerade SF-36 PCS högt med HAQ och måttligt 
med symtom på HAQ-VAS-allmänt, dyspné, smärta och fysisk kapacitet, medan 
SF-36 MCS korrelerade måttligt med ångest och depression (HAD).
Slutsatser: Även om patienter med SSc rapporterade lägre fysisk kapacitet och 
mer begränsande faktorer för fysisk kapacitet än kontroller, fanns inga skillnader i 
rapporterad fysisk aktivitet och stillasittande under dagen. Patienter med SSc hade 
emellertid markant lägre muskeluthållighet i både övre och nedre extremiteter, 
minskad muskelstyrka i nedre extremiteterna och nedsatt skulder-armrörlighet. 
Patienter med måttlig–mycket svår lungsjukdom hade lägre muskeluthållighet och 
mindre styrka än de med ingen–mild lungsjukdom, men överraskande fanns inga 
skillnader mellan lcSSc och dcSSc. Bland personer med SSc med ingen–mild, och 
måttlig–mycket svår lungsjukdom, uttrycktes det att fysisk aktivitet och träning var 
nödvändigt för liv och hälsa, och att det minskade rädslan för försämring. Dock 
uttrycktes det även att det fanns en risk för negativa konsekvenser av fysisk aktivitet 
och träning. Eftersom patienter med SSc med måttlig–mycket svår lungsjukdom 
hade lägre fysisk kapacitet, var mindre fysiskt aktiva samt tränade mindre, hade 
mer fysiska funktionshinder, hade lägre fysisk HRQoL och mer depressiva symtom 
än patienter med ingen–mild lungsjukdom, kan individanpassad fysisk aktivitet 
och träning vara av nytta. Delarbetena som ingår i denna avhandling bidrar till ny 
kunskap om hur man kan utveckla framtida träningsprogram, inklusive uthållig-
hetsträning för patienter med SSc, speciellt för de med svårare lungsjukdom. 
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11 INTRODUCTION
1.1 Systemic sclerosis 
Systemic sclerosis (SSc) is a rare autoimmune systemic disease characterised by vas-
culopathy, fibrosis and autoimmunity [1,2]. The American Rheumatism Association 
published the first classification criteria for SSc in 1980 [3]. The criteria were revised 
and updated by the 2013 American College of Rheumatology/European League 
Against Rheumatism (ACR/EULAR) [4], (Table 1). The classification criteria include 
the skin, lesions, abnormalities in blood vessels, cardiopulmonary manifestations 
like pulmonary arterial hypertension (PAH) and lung fibrosis/interstitial lung disease 
(ILD). A total score is calculated through adding the maximum score in each of the 
eight sub-items. Patients with total score ≥9 are considered to have definite SSc. 
Tight skin on fingers on both hands extending proximal to the metacarpophalan-
geal (MCP) joints is considered as a sole criterion for SSc. Based on the extent 
and location of skin involvement SSc is traditionally grouped into two distinctive 
subtypes; limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) [5-7]. 
In patients with lcSSc skin tightness is limited to parts distal to elbows or knees, 
whereas those with dcSSc have more widespread skin changes affecting proximal 
limbs and/or trunk. Face involvement can be present in both subtypes [6,7]. This 
clinical classification can be considered as a help to classify patients according to 
presence and extent of skin involvement, and also to predict future internal organ 
disease and survival [6].
Raynaud’s phenomenon (RP) is together with involvement of the gastrointestinal 
tract (GI) the first symptoms of SSc and they are almost universal in both subtypes 
of the disease [6].
Recent research highlights the importance of investigating the presence of anti-
nuclear antibodies (ANA) in patients with SSc, since the autoantibody pattern helps 
to improve diagnosis and identification of disease subsets as wells as to improve 
patient’s care and management [8,9]. Over 90% of patients with SSc display ANA 
[1,10]. The most common and clinically relevant subsets of ANA in SSc are anti-
topoisomerase I antibodies (ATA) and anti-centromere antibodies (ACA) [1,10]. In 
Caucasian populations ACA is more common than ATA, occurring in up to 90% and 
40% respectively [10-12]. The presence of ANA is often present prior symptom onset 
and titres of ANA are often stable during the course of the disease [6]. The ANA-
subgroups are in most cases associated with different clinical patterns of disease.
2Table 1. The American College of Rheumatology/European League Against 
Rheumatism criteria for the classification of systemic sclerosis (SSc) [4]. 
Item Sub-item(s) Score
Skin thickening of the fingers of both 
hands extending proximal to the MCP 
joints (sufficient criterion)
- 9
Skin thickening of the fingers (only count 
the highest score)
Puffy fingers
Sclerodactyly of the fingers  
 (distal to the MCP but proximal 
to the  interphalangeal joints)
2
4
Fingertip lesions (only count the highest 
score)
Digital tip ulcers
Fingertip pitting scars
2
3
Telangiectasia - 2
Abnormal nailfold capillaries - 2
PAH and/or ILD (maximum score is 2) PAH
ILD
2
2
RP - 3
SSc-related ANA’s (maximum score is 3) ACA
ATA
A-RNA III
3
3
3
MCP: metacarpophalangeal; PAH: pulmonary arterial hypertension; ILD: interstitial lung disease; 
RP: Raynaud´s phenomenon; ANA: anti-nuclear antibodies; ACA: anti-centromere antibodies; 
ATA: anti-topoisomerase I antibodies; A-RNA III: anti-RNA polymerase III antibodies. The total 
score is determined by adding the maximum score in each category and a total score ≥9 is 
 considered as having definite SSc.
The incidence and prevalence of SSc varies globally depending on regions and 
ethnicity. The reported incidence varies between 4–43 per million and the preva-
lence between 70–340 per million [13]. In a study published 2014 [14], including 
all residents in Skåne, the southernmost region of Sweden with a population of 
1.3 million inhabitants, the adult annual incidence and prevalence of SSc were 
14 and 235 per million, respectively. Between 60–80% of the patients worldwide 
are diagnosed with lcSSc, while approximately 20–40% of patients have dcSSc 
[2,5]. The Swedish study showed that 82% of the prevalent cases were diagnosed 
with lcSSc [14]. As in many other rheumatic diseases female gender predominates 
in patients with SSc with a female/male ratio of 6:1 [1], however the gender ratio 
differs between the two diagnostic subgroups with a ratio of 11:1 in lcSSc and 
4:1 in dcSSc [1].
31.2 Organ manifestations and disease severity
Several different organ systems can be affected in SSc, and the extent of disease 
damage and disease severity is often assessed by the Medsger disease severity scale 
[15] which grades nine areas affected by the disease: (1) General, (2) Peripheral 
Vascular, (3) Skin, (4) joint/tendon, (5) Muscle, (6) Gastrointestinal tract, (7) Lung, 
(8) Heart and (9) Kidney. The scale measures disease damage between 0, indicating 
normal function/no impairment or damage, to 4, end-stage. The end-stage score 
of 4 points means that a patient is dependent of supplemental oxygen if the score 
4 occurs in the organ system Lung, and when a 4 is scored in the organ system 
Heart it means that the patient is suffering from congestive heart failure and has 
a left ventricular ejection fraction of <30%. 
Skin thickness is usually measured by the modified Rodnan skin score (mRSS) 
[16]. The mRSS is also included in the Medsger disease severity score as part of 
the organ system Skin [15]. 
1.3 Fibrosis and vasculopathy
1.3.1 Fibrosis
Fibrosis of the skin is one of the hallmarks of SSc and the term scleroderma, hard 
skin, is used to describe the hard woody like skin feature [17]. The fibrotic changes 
do not only affect the skin but also different internal organs such as the GI, the 
lungs and the heart [6]. Diffuse cutaneous SSc is associated with earlier occur-
rence of severe lung fibrosis/ILD, cardiac fibrosis and an overall worse prognosis. 
The ILD is due to thickening of the interstitium caused by autoimmunity and/or 
inflammatory processes [2,5,18–20]. 
1.3.2 Vasculopathy
The vascular spasm in RP is episodical, painful, and mainly affects fingers or toes 
but also the nose and ears. The ischemia is mainly provoked by exposure to cold 
temperatures, changes in temperatures and/or stress [6,21]. More than 50% of patients 
have a history of digital ulcers, and approximately 10% of all patients with SSc 
currently have digital ulcers [22]. The pathophysiology of digital ulcers is multi-
fold, and often vasospasm and vasculopathy (e.g. intimal fibrosis and  endothelial 
dysfunction) are contributing factors [23]. Not only are ulcers very painful, digital 
ulcers also take a very long time to heal [22]. The most feared and severe form 
of vasculopathy is PAH [23,24]. Albeit patients with SSc can be affected by all 
forms of pulmonary hypertension, PAH is the most common type [25]. The vas-
cular disease in the lungs in SSc is characterized by narrowing and occlusion of 
the pulmonary arteries. The risk factors for developing isolated PAH are long 
disease duration, presence of ACA and the belonging to the lcSSc subtype [26]. 
41.4 Cardiopulmonary function in SSc
1.4.1 Consequences of cardiopulmonary symptoms
Lung fibrosis and PAH are two common and serious consequences of the disease, 
both leading to a decline in lung function [23,27]. They are potentially lethal com-
plications and the most common causes of death in SSc [6,28] with lung fibrosis-
related mortality in 19%, isolated PAH in 14% followed by myocardial (overall) 
causes in 14% [28]. 
Dyspnoea is a cardinal symptom of both ILD and PAH and indicate a more severe 
form of disease, however, dyspnoea at exertion can also be a symptom of decondi-
tioning due to inactivity [29]. Regardless of origin, dyspnoea, or shortness of breath/
breathlessness is often experienced by patients with SSc [30]. 
1.4.2 Assessment of cardiopulmonary function
The use of high-resolution computed tomography (HRCT) is a well-established 
method to assess signs of lung fibrosis/ILD in SSc [6,25,31]. Clinically relevant 
lung fibrosis is present in approximately 25% patients with SSc [25] but fibrosis/
ILD is observed in up to 90% of cases with SSc, if also subclinical lung fibrosis/
ILD is included [32]. 
By use of pulmonary function tests (PFT) the presence, and severity, of fibrosis can 
be detected [33]. The forced vital capacity (FVC) and diffusing capacity of the lung 
for carbon monoxide (DLCO) are both important variables. Values ≥80% of pre-
dicted FVC and DLCO are considered as normal in individuals without respiratory 
limitations [25], however, PFT also have certain disadvantages as the normal range 
of FVC is 80–120%. In cases where patients have an FVC and/or DLCO >80% of 
predicted values, but present progression of respiratory problems further evalua-
tions are needed [25,32]. The spirometry variable FVC [34] is a useful measure to 
predict prognosis and mortality in patients with lung fibrosis [26]. The risk factors 
for developing severe ILD are early dcSSc and ATA, especially in patients that have 
a reduction in FVC during the first 18 months since disease onset. Unlike idiopathic 
ILD the decline in FVC may stabilize around 60–70% of predicted values for many 
years [26]. Pulmonary function tests assessing DLCO [35] and transthoracic echo-
cardiography are recommended as to screen all patients with SSc for PAH [36]. 
1.4.2.1 Lung disease severity scale
The Medsger Disease Severity scale combines findings from PFT (DLCO and FVC) 
with the classification of (no)/presence of fibrosis on HRCT and elevated pulmonary 
arterial pressure to assess lung disease severity in SSc [15] (Table 2). Each measure 
is scored using the most severe of the included values in the scoring. In this Thesis 
patients with a score of 0–1 on the Medsger scale were classified as having no–mild 
lung disease and those with 2–4 as having moderate–end-stage lung disease. 
5Table 2. Disease severity of the lungs, according to the Medsger scale [15].
Organ 
system
0  
(normal)
1  
(mild)
2  
(moderate)
3  
(severe)
4  
(end-stage)
7. Lung DLCO ≥ 80%, 
FVC ≥ 80%, 
No fibrosis on 
radiograph, 
sPAP <35 mmHg
DLCO 70–79%, 
FVC 70–79%, 
basilar rales, 
Fibrosis on radio-
graph, sPAP 
35–49 mmHg
DLCO 50–69%, 
FVC 50–69%, 
sPAP 50–64 mmHg
DLCO <50%, 
FVC <50%, 
sPAP 65+ mmHg
Oxygen 
required
DLCO: diffusing capacity for carbon monoxide, % of predicted; FVC: forced vital  capacity, 
% of predicted; sPAP: estimated pulmonary arterial pressure by Doppler transthoracic 
echocardiography.
1.5 Range of motion
1.5.1 Tight skin
The skin changes in SSc may present in three phases where the initial phase is 
an inflammatory and oedematous stage where the fingers and hands appear puffy 
and swollen. In the second and longer phase various degree of sclerotic progres-
sive skin fibrosis occur, typically starting distal to the MCP joints. During this 
phase contractures in fingers and hands start. In the third phase, skin is gradually 
becoming softer and atrophic. The skin may return to a state of clinical normality, 
especially on the upper extremities and the trunk [6,37]. The tight skin may restrict 
active range of motion (AROM) in both upper and lower extremities [38,39]. Tight 
skin around the mouth can appear in both subtypes, and the characteristic micro-
stomia which limits mouth opening is present in about 70% patients [40]. Excess 
fibrotic tissue makes the skin hard and can impact facial mimicry and make oral 
care problematic [37]. Subcutaneous fat can also dwindle or disappear in both the 
face as well as the hands and feet [6,7]. The changes in appearance is problematic, 
especially among women [37]. 
1.5.2 Joints 
Progressive skin thickening/changes can give rise to contractures affecting mainly 
the fingers/hands in SSc. Joint involvement, both presented as generalized arthralgia 
with stiffness and slight pain as well as inflammatory arthritis, eventually affects 
between 46–97% of all patients with SSc [41]. These alterations can cause reduc-
tions in grip strength and impaired dexterity [6,38]. Joint contractures affect about 
1/3 and causes functional disability due to skin sclerosis, tendon shortening and/
or joint destruction [42]. Several studies have shown that patients with dcSSc, 
but also lcSSc, are affected by severe AROM impairments [43–45]. In addition, 
contractures (reductions in ROM <75% of normal values), are very common in 
wrists and hands affecting more than 75% of patients with SSc. Larger joints like 
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15% while contractures are found to a lesser extent in the lower extremities, in 
approximately 10% in hip, knee and ankle [44,46]. Limited AROM in the lower 
extremities has also been found in SSc, especially in dcSSc [39,47]. Yet, there is 
limited insight on the impact of lcSSc/dcSSc to what extent functional AROM in 
activities of daily living (ADL) is affected in the shoulder-arm region and whether 
this influence the possibilities to be physically active (PA) and exercise. 
1.6 Muscle strength and muscle endurance
Muscle involvement in SSc varies widely but is reported to be present in between 
5–96% of patients [48] and is more common in dcSSc than in lcSSc [1,48].The big 
diversity in reported frequency is mainly due to different methods when assessing 
muscle involvement and also lack of consistently accepted definition of myopathy 
[48]. Proximal muscle weakness in shoulder and hip-pelvic region is a prominent 
symptom in SSc [6,49]. Functional strength, as in standing up from a sitting posi-
tion, is also reduced in comparison with normative data. Differences between 
subtypes of SSc are present as patients with lcSSc can perform more sit-to-stand 
movements than patients with dcSSc. Patients with SSc were more limited in the 
timed up and go test compared to normative data [39]. Muscle endurance in the 
quadriceps muscles has also been found to be reduced in comparison with con-
trols [50]. Others have used tests like the Keitel functional test, and the 30-second 
timed sit-to-stand, that both measures muscle function in the lower extremities 
[39]. Muscle strength as well as muscle endurance can also be assessed with an 
isometric dynamometer [50]. Nonetheless, there is a dearth of knowledge about 
how muscle strength and muscle endurance is affected, especially in patients with 
different degrees of lung disease, and what consequences muscle impairment has 
in the lives of patients with SSc. 
1.7 Pain and tiredness/fatigue
Pain is a common symptom in patients with SSc [30] with arthralgia and myalgia 
among the earliest musculoskeletal symptoms [6]. The frequency of self-reported 
pain has been reported as ~85% in joints, ~75% in muscles as well as ~55% in 
skin [30]. Pain originating from RP is one of the most frequently reported symp-
toms in SSc [30,51]. Furthermore, digital ulcers are also very painful [22]. There 
is a lack of knowledge on how patients with SSc perceive pain in relation to PA/
exercise and physical capacity and whether there are any differences in regard 
to lung involvement. Fatigue is another disease-related symptom affecting many 
patients with SSc. This overwhelming tiredness is not only very frequent, but 
also one of the symptoms with highest impact on everyday activities [30]. Severe 
fatigue is associated with more pain, worse sleep quality and greater depressive 
symptoms [52].
71.8 Disability
Due to the heterogenous nature of SSc different degree of limitations in function 
can be encountered. Primarily the hands are affected but also the face is affected 
by local disability [37]. Among patients with SSc ADL can be a major problem 
as finger flexion and extension and grip strength has been found to be impaired 
in comparison with healthy persons [38]. Not only activities involving the upper 
extremities, like dressing or lifting/holding objects and other household activities, 
are affected, the lower extremities are also influencing the possibilities to partake 
in activities. It has been reported that climbing stairs, getting in/out of a car and 
leisure activities like sports are troublesome [30,53].
Patients with dcSSc have more disabilities compared to patients with lcSSc when 
assessed with the Health Assessment Questionnaire Disability Index (HAQ-DI) 
[54,55]. There are little if any correlations between FVC and DLCO and HAQ-DI 
but a moderate correlation has been presented between dyspnoea and HAQ-DI 
[56]. Yet no study has evaluated the impact of lung disease, as measured with the 
Medsger disease severity scale, on disability in SSc. 
1.9 Quality of life, anxiety and depression
1.9.1 Health-related quality of life
The World Health Organization defines quality of life as an individual’s perception 
of their position in life in the context of the culture and value systems in which 
they live and in relation to their goals, expectations, standards and concerns. It is a 
broad ranging concept affected in a complex way by the person’s physical health, 
psychological state, personal beliefs, social relationships and their relationship to 
salient features of their environment [57]. 
The term quality of life is, in the same way as health is, ambiguous and not easily 
given a distinct definition. Both concepts are reflecting different aspects of well-
being, but the quality of life has a considerably broader content. Health-related 
quality of life (HRQoL) means a pragmatic delimitation, and primarily relates to 
function and well-being during illness and treatments [58].
Measurements of HRQoL can be done with different self-reported questionnaires, 
but the generic Medical Outcomes Trust Short Form 36 (SF-36) is probably the most 
well-known and used tool, in SSc as well as in other populations and samples. The 
HRQoL, as measured by SF-36, has been found to be lower among patients with 
SSc compared with the general population, and patients with dcSSc have lower 
HRQoL than lcSSc [59]. Patients with dcSSc report lower scores on physical and 
mental aspects of HRQoL compared to patients with lcSSc [60]. Dyspnoea has 
been found to correlate with HRQoL whereas no correlations were found with 
objective lung damage in a study with lcSSc without signs of PAH [56]. Another 
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tive pulmonary disease (COPD) have lower scores in the physical HRQoL in 
relation to the general population [61]. So far, no study has evaluated the HRQoL 
in patients with different degrees of lung disease as measured with the Medsger 
disease severity scale. 
1.9.2 Anxiety and depression 
Due to the reduced life expectancy in dcSSc, which is associated with internal organ 
involvement [62] it is understandable that anxiety and depression symptoms are 
common in SSc [63]. Clinically relevant self-reported anxiety is more frequently 
reported in women, whereas men are more often free from symptoms of both 
anxiety and depression when measured with the Hospital Anxiety and Depression 
scale (HAD) [64]. If levels of anxiety and depression symptoms differ depending 
on degree of lung involvement as measured with the Medsger score is unknown.
1.10 Physical capacity and activity 
In this Thesis we define physical capacity as self-reported ability to walk, jog or 
run. Physical activity (PA) has been defined as any bodily movement that is pro-
duced by skeletal muscles and resulting in an energy expenditure. PA in the daily 
living can be categorized into household, occupational, conditioning, sports, or 
other activities. Exercise is a subset of physical activity that is planned, structured, 
and repetitive and has, as a final or an intermediate objective, the improvement 
or maintenance of physical fitness. Physical fitness is a set of attributes that are 
either health- or skill-related [65].
Reduced PA has been observed in patients with early SSc without pulmonary 
involvement, and nearly ¾ were below recommended levels of PA in compari-
son to only 27% of age- matched controls [66]. Likewise, in patients with lcSSc 
and with PAH reduced PA has been reported in comparison with patients without 
PAH [67]. Self-reported PA has also been found to be significantly lower among 
patients compared to the general Dutch population [68]. There are yet no publica-
tions presenting results whether there are any differences in PA between patients 
with no–mild and moderate–end-stage lung disease, nor between patients and true 
age- and gender-matched controls. 
Patients with SSc without lung involvement have a significantly lower aerobic 
capacity compared with healthy controls as measured by maximal exercise test 
on a treadmill [69]. Likewise did maximal ergometer testing show that patients 
with PAH had lower maximal oxygen uptake than patients without PAH, but both 
groups had a clear limitation in exercise performance when compared to predicted 
values [70]. How self-reported physical capacity is perceived in patients with 
SSc with different degrees of lung involvement, and if there are any differences 
between groups, remains unknown.
91.11 Experiences of Physical activity/exercise
In other chronic rheumatic diseases, such as rheumatoid arthritis (RA), PA/ exercise 
have been reported to be perceived as important contributors to symptom manage-
ment including pain relief and joint function. Both pain and fatigue as well as 
reduced mobility and stiffness have been reported as barriers to PA/exercise in 
RA [71]. Similar findings are presented in ankylosing spondylitis (AS) where 
pain, stiffness and fatigue were the main barriers to PA/exercise while the most 
often reported benefits of PA/exercise were improved fitness, increased vitality 
and improved mood [72]. Shortness of breath is experienced as a major barrier 
for PA/exercise in patients with pulmonary diseases such as COPD, while feel-
ing fit and having better breathing outcomes, and support from others, like health 
professionals such as physiotherapists, were facilitating factors [73].
However, very little is known about how patients with SSc perceive PA/exercise, 
and what experiences they have from being PA/exercise, nor what is considered 
as facilitating and hindrances. 
1.12 Pharmacological treatments
There are no curative treatments available for patients with SSc, however, many of 
the different symptoms can be alleviated by pharmacological drugs [7]. Intensive 
research is underway, and many patients have already had their disease burden 
eased by use of immunosuppressive treatments as well as blood vessel modulat-
ing treatments [7]. 
1.13 Non-pharmacological treatments
In the newly revised recommendations for Modern Rheumatological Rehabilitation 
(MoRR) the aims of rehabilitation in rheumatic diseases are to regain and/or 
maintain physical function and participation in society [74]. This can be done by 
prevention, needs-driven individual interventions, team rehabilitation in an out-
ward setting, and after this, in an in-ward setting. Regardless rehabilitation level 
physiotherapists are key-players as they, as well as PA/exercise, are fundamental 
in the rehabilitation of patents with rheumatic diseases [74].
Because no curative pharmacological treatments are available for patients with 
SSc rehabilitation is a possible way to ease the disease burden. However, there is 
limited knowledge and guidelines about non-pharmacological care in SSc, mainly 
because of the large variety in studied interventions as well as in the outcomes. 
Furthermore, the studied samples are in many cases small and/or lacking control 
groups [37,75]. Our research group, in collaboration with Brazilian researchers, 
have in a literature review found that physical exercise in patients with SSc with 
no or mild lung disease has shown positive effects concerning physical capacity, 
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HRQoL and could be considered safe [76]. However, there are few studies [76] 
concerning the effects of exercise in patients with SSc with moderate to severe 
lung disease. But improvements in aerobic capacity [77] and muscle endurance 
[78] have been reported in patients without ILD after participation in exercise 
programmes. In a small study in patients with SSc with and without pulmonary 
involvement, increased muscle strength and aerobic capacity was seen after 12 
weeks resistance and aerobic exercises [79]. The aims in hand rehabilitation are 
to improve both movement and strength in hands, and ameliorate participation 
in ADL like personal self-care, house-hold activities and leisure activities [37]. 
Different techniques to treat musculoskeletal impairments have been used with 
various results [80]. Hand stretching was beneficial [81], as was connective tissue 
massage [82]. Paraffin wax bath in combination with hand exercise has also been 
found to improve function more than sole exercise [83]. 
1.14 Clinical outcome measures in SSC
1.14.1 Range of motion
Goniometer is often used by physiotherapists, as well as occupational therapists, 
when measuring active and passive ROM, as has been used in previous studies 
[44,46,84]. Another way to assess AROM in the upper extremities in rheumatic 
diseases is with the Functional Shoulder Assessment (FSA) [85]. This instru-
ment was originally developed for patients with RA. In the original version of 
FSA four tasks were assessed [85], but a revised version with five tasks has been 
developed [86]. 
1.14.2 Muscle function
Muscle strength, and muscle endurance, can be measured in different ways. An 
isometric muscle test measures muscle function in a static position, the muscle 
tries to contract but does not change in length, whereas in an isotonic muscle test 
the muscle changes in length. Functional muscle strength in the lower extremities 
can be measured with the Timed-Stands Test (TST) [87]. Another, similar test, is 
the 30-second timed sit-to-stand, that also measures muscle function in the lower 
extremities [88]. The Timed Up and Go test can also be used as a physical fitness 
test for assessing agility/dynamic balance [89].
Muscle strength has often been measured by use of the manual muscle test (MMT), 
however this instrument is limited by ceiling effects in patients with mild muscle 
strength weakness [48]. Dynamic repetitive muscle endurance can be measured 
with Functional Index-2 (FI-2), an instrument originally developed for patients 
with myositis [90]. 
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1.14.3 Pain and tiredness/fatigue
Pain can be assessed in various ways, either by use of a numeric rating scale [91], 
visual analogue scale (VAS) [92], or self-reported HRQoL such as in SF-36 [58]. 
Assessments of fatigue can be done with several different questionnaires [93,94]. 
1.14.4 Disability
The HAQ instrument is a self-reported questionnaire that has become one of 
the key instruments used when assessing disability and function in rheumatic 
 musculoskeletal disorders. Included in the HAQ is a disability index (HAQ-DI). 
The HAQ-DI has been adopted to the context of SSc, Scleroderma HAQ (SHAQ) 
by having five VAS added [95], otherwise than this both HAQ and SHAQ are 
scored the same way [96]. The five VAS measures pain, patient general assessment, 
vascular, digital ulcers, lung involvement and gastrointestinal involvement [95,96].
1.14.5 Health-related quality of life
There are several instruments that are used to assess HRQoL, both generic and 
diseases/symptom-specific. One generic is the EuroQol instrument, subsequently 
called EQ-5D [97] and another is the well-known Medical Outcomes Study 
36-short form (SF-36) [98]. The St George’s Respiratory Questionnaire (SGRQ) 
was originally developed to assess HRQoL in patients with COPD but it has also 
been used in patients with idiopathic pulmonary fibrosis [99].
1.14.6 Anxiety and depression
The HAD scale was developed to identify possible and probable cases of both 
anxiety and depression disorders. The HAD scale consists of seven questions each 
for the anxiety dimension (HADa) and depression dimension (HADd) [100]. In an 
attempt to prevent disturbances from physical disorders like insomnia, dizziness, 
fatigue and headaches, symptoms that were related to anxiety and/or depression 
were excluded from the scale [100]. 
1.14.7 Self-reported physical activity/exercise and 
physical capacity
Self-reported physical activity has often been assessed by the International Physical 
Activity Questionnaire and there are different versions of the instrument available, 
and also various forms of administration of the questionnaire; as by telephone 
interviews or by self-administration [101]. Another self-reported questionnaire is 
the Physical Activity Questionnaire (PAQ) that has been used in systemic lupus 
erythematosus (SLE) in Sweden [102,103]. The latter questionnaire also assesses 
exercise, physical capacity along with time spent sitting during day. 
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1.15 Qualitative content analysis
Experiences of PA/exercise are preferably explored with qualitative research 
methods as this approach may facilitate a more in-depth understanding of a group 
of individuals experiences [104]. By using a qualitative method, it is possible to 
evaluate and gain a deeper understanding in different perspectives [105]. The 
inquisitive use of qualitative methods can be used when there is insufficient, or 
a lack of information about a certain topic like how patients with SSc experience 
PA/exercise. Content analysis is an often-used method in nursing and healthcare 
research [106,107]. A face-to-face interview can often last between 30 and 90 
 minutes. Use of a semi-structured interview guide is recommended as it enhance the 
topics of interest that will be covered by every informant. About 15–20 individual 
interviews or three-to-four focus group discussions are often enough, depending 
on data saturation [108].
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2 THESIS RATIONALE
Systemic sclerosis is a major cause of disability and increased morbidity as well 
as mortality. The large diversity of how the disease presents itself; lcSSc/dcSSc, 
quick progression or stable disease, damage of varying severity in different organ 
systems, combined with the rarity makes it challenging to both study the disease, 
and to adequately treat the patients. 
Little is known about how, and if, self-reported levels of physical capacity and 
PA/exercise differ between patients with no–mild and moderate–end-stage lung 
disease. Likewise, there is a dearth of knowledge as to what extent muscle function 
and AROM is affected in different subphenotypes of SSc. Nothing has yet been 
published about how patients with SSc experience PA/exercise, nor what factors 
are perceived as facilitating, or as hindrances. However, it is well known that 
patients with SSc have reduced HRQoL, that they often have disabilities affecting 
their ADL, and that they suffer from symptoms of both anxiety and depression. 
But less is known about differences/similarities between patients with no–mild 
and moderate–end-stage lung disease. 
Increased knowledge about physical capacity, levels of PA/exercise on  different 
levels of intensity in addition to further knowledge about how much muscle 
strength, muscle endurance and AROM is affected in SSc, can help develop exer-
cise programs suitable for patients with different degrees of lung disease. Also, by 
increased insight into how patients experience PA/exercise and what they perceive 
as facilitating and/or hindrances can improve patient education and support to those 
in need. With the aim to optimize health for patients with SSc, PA/exercise is an 
important, and often neglected, addition to medical treatment. This taken together, 
can hopefully help to increase HRQoL in patients with SSc. 
14
3 AIMS
The overarching aim of this Thesis was to increase knowledge about physical 
function, physical activity and quality of life in patients with SSc and different 
degrees of lung disease. 
The aims of the included papers were:
I. To investigate potential differences in self-reported physical capacity and 
activity between patients and an age- and gender-matched population-based 
control group, as well as between patients with normal–mild and moderate– 
severe lung disease and their respective controls. 
II. To examine functional dynamic muscle endurance in the shoulder and hip- 
girdle, functional dynamic muscle strength in the lower extremities, and 
functional AROM of the shoulder-arm region in patents with SSc. 
We also explored possible differences depending on SSc subphenotypes; i.e. 
lcSSc versus dcSSc, and presence of mild versus severe lung involvement.
III. To explore and describe experiences of PA/exercise in individuals with SSc. 
IV. To explore differences/similarities with focus on HRQoL, disabilities, PA/
exercise and physical capacity between patients with no–mild lung disease 
and moderate–end-stage lung disease.
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4 PARTICIPANTS AND METHODS
4.1 Study designs
In the papers included in the Thesis, different research designs were used, see 
Table 3.
Table 3. Overview of the research designs of the papers included in the Thesis.
Paper Design Specific analysis methods a
I Cross-sectional cohort study 
 compared with an age- and gender 
matched population-based controls
Pearson’s ᵡ2 or Fisher’s exact test,  
Mann-Whitney unpaired test, Student’s 
t-test.
II Cross-sectional cohort study 
 compared with reference values
Pearson’s ᵡ2 or Fisher’s exact test,  
Mann-Whitney unpaired test, Wilcoxon 
signed-ranks test.
III Interview study using exploratory 
descriptive qualitative design 
Content analysis, inductive approach
IV Cross-sectional cohort study 
 compared with reference values
Pearson’s ᵡ2 or Fisher’s exact test,  
Mann-Whitney unpaired test, independent 
samples t-test, Spearman’s correlation 
coefficient
a descriptive statistics were used in all papers in the Thesis. 
4.2 Participants, reference values used in the studies, 
and procedures
All patients with SSc are part of the Karolinska University Hospital’s SSc-cohort, 
which consists of patients living in the greater Stockholm region. Demographic 
and clinical characteristics are presented in Table 4. 
4.2.1 Paper I
A total of 106 adult patients with SSc and 106 age- and gender-matched popu-
lation-based controls living in the Stockholm County were included. All partici-
pants were recruited between 2006 and 2009. The control persons were recruited 
by use of the national identification number which is coded for gender and date 
of birth. The gender-matched person with the birth date closest to the respective 
patient was contacted and asked to participate in the study. If the “first choice” 
declined participation, the second closest was asked, until control person gave 
her/his consent. In 65 % of cases the “first choice” accepted and participated in 
the study. The only exclusion criterion was a diagnosis of SSc. All patients, and 
controls, answered the PAQ. 
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The PAQ instrument covers different self-reported aspects of physical capacity, 
PA and time spent sitting as well as exercise. The PAQ used in this Thesis have 
moderate to almost perfect test-retest reliability (weighted kappa coefficients 
0.55–0.87) as suggested by Landis and Koch [109] and satisfactory content  validity 
in patients with SLE [103]. 
As part of this Thesis the test-retest reliability of the PAQ was performed on a 
subgroup (n=51) of patients with SSc. The test-retest reliability was moderate 
to substantial. The questions regarding PA on a low-moderate intensity past six 
months had a weighted kappa: 0.57, 95% CI (0.39–0.81), PA on a high intensity past 
Table 4. Demographic and clinical characteristics of patients included in the Thesis.
Characteristics Paper 1 Paper II Paper III Paper IV
Participating patients and 
controls, n
106+106 
controls
205 16 279
Age, years 61±12 60 (52–69) 53 (24–73) † 60 (52–69)
Women, % 84 82 81 83
LcSSc/dcSSc, % 79/21 82/18 75/25 84/16
No–mild/moderate–end-
stage lung  disease, %
55/45 59/41 50/50 58/42
Disease duration, years 9±9 8 (3–13) 8 (1–38) † 5 (2–11)
Medsger disease severity
    General, % ‡
na 88/10/1/0/1 na 89/10/1/0/06
    Peripheral vascular, % ‡ na 17/61/13/8/12 na 14/62/13/10/17
    Skin, % ‡ na 9/81/9/1/0 na 10/83/6/1/0
    Gastrointestinal, % ‡ na 30/55/13/1/113 na 28/59/12/1/016
    Lung, % ‡ 28/26/34/10/2 27/31/29/12/16 19/31/31/6/13 28/30/29/12/18
    Heart, % ‡ na 80/14/2/2/26 na 81/14/3/1/112
    Kidney, % ‡ na 95/4/9/1/13 na 94/4/0/1/18
Pulmonary hypertension, % 8 6 na 81
Lung fibrosis, % 46 38 na 401
DLCO (% of predicted), % 72±195 na na 74 (61–86)10
FVC (% of predicted), % 84178 na na 87 (76–98)12
Values are presented as mean±(SD), % or median (IQR); †: Median (min-max); ‡: Medsger 
disease severity score 0/1/2/3/4; DLCO: diffusing capacity of the lung for carbon monoxide; 
FVC: forced vital capacity
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6 months: 0.66, 95% CI (0.35–0.96), Physical capacity: 0.58, 95% CI (0.42–0.74), 
Time spent sitting during the day: 0.74, 95% CI (0.47–1.0), and, Exercise past 
year: 0.74, 95% CI (0.52–0.96).
4.2.2 Paper II
In this study 205 patients with lcSSc/dcSSc were divided into no–mild and 
 moderate–end-stage lung disease. All patients who had performed physical assess-
ments at the physiotherapy department at the Unit of Rheumatology at Karolinska 
University Hospital, Solna, between September 2006 and May 2017 were included. 
The FSA was used to measure AROM in the shoulder-arms, FI-2 assessed dynamic 
muscle endurance in upper and lower extremities, TST was used to measure func-
tional muscle strength in the lower extremities. 
For FSA, reference values from the general Swedish population, in intervals of 
10  years, was used. These reference values are presented by Olofsson et. al. [110] 
and in the present study we had access to their original data. In the Olofsson-study 
they used an earlier version of FSA which consisted of four tasks. The included 
tasks are assessed on a 6-point Likert scale (1 point being the worst possible func-
tion and 6 points is no impairments in AROM), resulting in a total maximum score 
of 24 points per shoulder-arm in the 4-task version and 30 points in the 5-task ver-
sion. Also, in the original FSA, the task Hand-to-neck was scored as 1–7 points, 
we converted this part to 1–6 points as it is scored this way in the most recent 
version. In this new version the task hand-to-seat has been added giving a total 
of 30 points for each shoulder. The comparison of results in the patient group and 
subjects from the general Swedish population was done by using results previ-
ously presented by Olofsson et. al. [110] in intervals of ten years which used the 
4-task version of FSA. When comparing different subphenotypes of patients with 
SSc we used the newer, 5-task version of FSA [86]. 
The FI-2 is commonly used in clinical settings in Sweden. Seven different muscle 
groups can be assessed and graded separately. In the Thesis shoulder flexion and 
hip flexion were assessed. The shoulder flexion was assessed in a sitting  position 
with a 1 kg weight cuff around the wrist. The hip flexion was assessed in a supine 
position with a straight leg. A pace of 40 beats/minute resulted in a pace of 20 
repetitions/minute. The maximal number of repetitions (60 per shoulder and leg) 
was registered. The results can be presented as counts or percentages of maximal 
repetitions per task. Preliminary reference values have been collected at Karolinska 
University Hospital, Solna, Sweden (HA), and at the Oslo University Hospital, 
Norway (RWH). These reference values are based on age intervals of 10 years 
from the general population. The comparison of patients’ FI-2 results with refer-
ence values was done on the right side only, due to 88% of reference values being 
assessed on the right side. 
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The FI-2 has been found to have “good” to “excellent” intra-rater, and, inter-rater 
reliability and it does also have a good construct validity in patients with myositis 
[90], however the test has not been validated in SSc yet.
For the TST, the time needed to complete ten full stands, without help from the 
hands, from a sitting position is recorded. Reference values for TST, based on 
gender- and age-matched healthy subjects, in intervals of 5 years, was used when 
comparing with patients’ assessments. The TST has been validated in several 
rheumatic and other chronic diseases [111].
4.2.3 Paper III
Sixteen patients strategically identified to represent both lcSSc/dcSSc and no–
mild and moderate–end-stage lung disease as well as both sexes, various age, and 
disease duration were interviewed between August 2017 and February 2018. The 
individual interviews were performed at a secluded room at Karolinska University 
Hospital, Solna. Each interview took in average 30–60 minutes. 
4.2.4 Paper IV
In this study 279 patients were included between September 2006 and December 
2018. To be included in the study the participants had to understand Swedish 
well enough to be able to fill in at least two of the four questionnaires used. The 
questionnaires used were SF-36, HAQ-DI including the five SSc-specific VAS, 
PAQ, and HADa/d.
The generic HRQoL questionnaire SF-36 assesses four physical health domains; 
Physical Function, Role Physical, Bodily Pain, General Health, and four mental 
health domains; Vitality, Social Function, Role Emotional, and Mental Health. 
Each domain is scored separately using an item weighting and additive scale. The 
summed data are then transformed onto a 0–100-point scale. The higher score, 
the higher quality of life. The scores can be added into global scores; physical 
component score (PCS) and mental component score (MCS) [98]. The PCS and 
MCS are standardized to responses from the general Swedish population and they 
have a mean score of 50 and a standard deviation of ±10 [112]. 
The HAQ-DI comprises 20 items that are divided into eight functional domains, 
each of which has two or three component questions adding up to a total of 20 items. 
The overall score is calculated by adding the highest item score in each of the eight 
functional domains and then dividing the sum by eight resulting in a score range 
between 0–3, where 0 means no disability whereas 3 indicate severe disability. The 
VAS measures self-reported problems the past week; pain, intestinal,  breathing, RP 
and digital ulcers, and also, overall problems today. The within-patient test-retest 
has been found to be very good, and the validity is also very high [96].
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Both the anxiety and depression dimensions that are part of HAD have seven 
questions each, and each question is scored between 0–3. The total score in each 
dimension ranges from 0, no clinical symptoms of anxiety or depression, to 21, 
maximal clinically significant symptoms. Scores between 0–7 are considered as 
normal, between 8–10 as borderline, and 11 or more as clinically relevant [100]. 
The instrument has been used in several studies in SSc, but it has not been specifi-
cally tested for reliability or validity in SSc [63].
4.3 Data analysis
P-values <0.05 were considered statistically significant in papers I, II and IV. All 
analyses were done on version 23.0 and 24.0 of IBM SPSS Statistics for Windows 
(IBM, Armonk, NY, USA). 
4.3.1 Paper I
In paper I differences in nominal variables, like gender, reported limiting factors 
to physical capacity such as poor fitness yes/no, or exercise past year ≥3 times/w, 
were analysed with Pearson’s ᵡ2 or Fisher’s exact test, when appropriate. The sig-
nificance of differences between groups were either calculated by Mann-Whitney 
unpaired test or Student’s t-test when appropriate for continuous variables.
4.3.2 Paper II
In paper II Pearson’s ᵡ2 or Fisher’s exact test was used when analysing differ-
ences in nominal variables, Mann-Whitney unpaired test was used for ordinal and 
non-normally distributed continuous variables whereas the Wilcoxon signed-ranks 
test was used when comparing observed values in the SSc-group with age- and 
gender-specific reference population values. 
4.3.3 Paper III
In paper III content analysis as described by Graneheim and Lundman was used 
[107]. The analysis procedure followed a latent content analysis which made 
it possible to distil the content of the performed interviews into fewer content-
related subcategories and categories. The categories were then grouped into 
over-arching themes. The latent content explores the interpreted meaning in the 
interview-material.
To get a rich variation of experiences of PA/exercise a purposeful sampling strategy 
was used [105]. This can help to ensure that a diversity of experiences is gathered 
in the sample of informants/patients with different degrees of lung involvement, 
age, gender and mix of lcSSc/dcSSc is included. A broad participation of differ-
ent degrees of disease severity and other parameters increases the transferability 
(external validity) of the findings to other patient groups in other settings.
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The analysis started by familiarization through re-reading the transcribed interviews 
while listening to the tape recordings. This process was followed by condensation 
and coding of meaning units, i.e. constellations of words and sentences belonging 
to the same central meaning in relation to the aim of the study. In order to increase 
the credibility of the findings, investigator triangulation was performed with a senior 
researcher, an co-author of the manuscript, experienced in  qualitative research [113]. 
Grouping and labelling of subcategories and categories were done in an iterative 
way by frequently returning to the transcripts as well as to the condensations and 
codes for additional reading to remain in line with the data. The codes were grouped 
into sub-categories which were then grouped into categories with similar content. 
The categories were labelled to cover the content of the included subcategories. 
To further increase the credibility of the analysis the preliminary categories were 
peer-reviewed in a multi-professional rheumatology healthcare research network 
group consisting of nurses, occupational therapists and physiotherapists. Main 
categories were developed by the Author and the senior researcher and discussed 
with another experienced researcher/co-author [107,114]. The main categories 
were further developed and sorted into overarching themes and then reviewed by 
the other researchers involved in the project [107] (Table 5).
Table 5. Steps and actions in the analysis in Paper III.
Steps Actions
1 Transcription and familiarization 
Verbatim transcription, reading and re-reading to get at good grasp of each 
 interview’s content
2 Condensation of meaning units
Condensation of interviews into meaning units 
3 Coding
Coding of meaning units
4 Sorting, grouping, and labelling subcategories
Sorting and grouping of codes into subcategories 
5 Organising subcategories into categories 
Subcategories combined into preliminary categories
6 Categories and Themes 
Main categories were further merged into three overarching themes
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4.3.4 Paper IV
In paper IV Pearson’s χ2 or Fisher’s exact test was used in the same way as in 
paper I and II, Mann-Whitney unpaired test was used when analysing differ-
ences in ordinal or non-normally distributed continuous variables, the independent 
samples t-test was used when analysing results from SF-36 in order to be able to 
compare with reference values. The Spearman’s correlation coefficient (r s ) was 
used to investigate relationships between SF-36 (PCS and MCS) and other vari-
ables. The r s-values were interpreted as suggested by Munro [115]: r s ≤ 0.25 no if 
any correlation; r s = 0.26–0.49 low; r s = 0.50–0.69 moderate; r s = 0.70–0.89 high; 
and r s = 0.90–1.00 very high correlation.
4.4 Ethical approval
The research included in the Thesis has been carried out in accordance with the 
Helsinki Declaration [116]. None of the studies involved any serious medical risks 
to the patients. The collection of data and publication of results have been carried 
out to guarantee the integrity and anonymity of the patients. All patients signed 
written informed consent and were reassured that participation was voluntary and 
that if they chose not to participate their care at the hospital would not be affected. 
All studies included in the Thesis were approved by the Stockholm Regional 
Ethics Review Board. 
Approval numbers: Paper I: dnr 2006/259-31/3. Paper II: dnr 2006/259/31/3 and 
2017/591-32. Paper III: dnr 2017/1134-31. Paper IV: dnr 2006/259-31/3 and 
2017/591-32. 
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5 RESULTS
5.1 Paper I: Self-reported physical capacity and activity
Patients with SSc had overall a lower self-reported capacity for walking, jogging, 
and running than age- and gender-matched population-based controls (Figure 1). 
The patients also reported more limiting factors for physical capacity (p<0.001) 
than the controls did. Both patients with no–mild lung disease and those with mod-
erate–end-stage lung disease reported lower physical capacity than their respective 
controls. Patients with moderate–end-stage lung disease reported cardiopulmonary 
disease (p<0.001) and reduced muscle strength (p=0.03) more often than their 
controls, whereas patients with no–mild lung disease reported pain (<0.05) more 
often than their controls as limiting factors for physical capacity. There were more 
patients (28%) that “never exercised” for at least 30 minutes/occasion the past year 
than controls (15%). Among the patients and controls there were no difference in 
exercise overall the past year or time spent sitting during the day. Likewise, no 
differences were found in PA past six months overall nor on a high intensity 4–7 
days/week, neither were any differences found in PA past six months on a low-
moderate intensity.
Figure 1. Self-reported physical capacity in patients with SSc (filled bars) and age- and 
 gender-matched controls. Patients with SSc had overall a lower physical capacity in comparison 
with the matched population-based control group (p<0.001). **p<0.01, ***p<0.001.
 
*** 
** 
** 
** 
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Patients with no–mild lung disease had overall a lower self-reported physical 
 capacity compared with age- and gender-matched population-based controls 
(Figure 2A). These patients reported more limiting factor for physical capacity 
(p<0.05), and pain (p<0.05) was more often reported as a limiting factor than in 
their matched controls. No other significant differences were found between the 
groups. 
Patients with moderate–end-stage lung disease did also have an overall lower 
 physical capacity (p<0.001) compared with their age- and gender-matched 
 population-based controls (Figure 2B). This subgroup of patients also reported 
more limiting factor for physical capacity (p<0.001), and reduced muscle strength 
(p<0.05) and heart or lung disease (p<0.001) were more often found to be a  limiting 
factor than among matched controls. Other than this there were no differences 
between the groups.
Figure 2 A and B. Self-reported physical capacity in patients with SSc and no–mild lung 
disease A, (filled bars) and moderate–end-stage lung disease B, (filled bars) and age- and 
gender-matched controls. 
(A) Patients with no–mild lung disease had overall a lower physical capacity in comparison 
with their matched population-based control group (p=0.001). 
(B) Patients with moderate–end-stage lung disease had overall a lower physical capacity 
than their matched controls (p<0.001). * p<0.05, **p<0.01, ***p<0.001.
** 
** 
* 
* 
Figure 2 A Figure 2 B
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5.2 Paper II: Muscle endurance, strength and active 
range of motion
Patients with SSc had reduced muscle endurance, when measured with FI-2, in 
both shoulder flexion as well as hip flexion in comparison with reference values. 
Differences in age groups are presented in Figure 3 A and B. Patients with  moderate–
end-stage lung disease had lower muscle endurance in both shoulder- and hip flex-
ion than patients with no–mild lung disease (Table 6). No differences in muscle 
endurance were found between patients with lcSSc and dcSSc.
Muscle strength, as assessed by the TST, in the lower extremities were overall lower 
in patients, as well as in both lcSSc and dcSSc, and, no–mild and moderate–end-
stage lung disease in comparison with reference values (Table 7). No differences 
in muscle strength in the lower extremities were found between lcSSc and dcSSc 
but patients with moderate–end-stage lung disease needed longer time to complete 
the test compared with patients with no–mild (Table 6).
Figure 3 A. Muscle endurance in shoulder flexion in right side in patients with systemic 
 sclerosis (SSc) and reference group divided in different age groups. The values for  shoulder 
flexion muscle endurance % of predicted according to Functional Index 2 in median. 
* p<0.05, **p<0.01, ***p<0.001.
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Table 6. Muscle endurance in shoulder- and hip flexion according to Functional Index 2 
(FI-2), and muscle strength in lower extremities, as measured with Timed-Stand Test (TST), 
in patients with systemic sclerosis (SSc) stratified by subtypes defined by skin involvement 
(limited or diffuse SSc) and subgroups defined by extent of lung disease (no–mild or 
moderate–end-stage).
All 
patients 
(n=205)
lcSSc 
(n=169)
dcSSc  
(n=36)
p- 
value
No–mild 
lung 
disease 
(n=116)
Moderate–
end-stage 
lung disease 
(n=82)
p- 
value
Shoulder flexion 
endurance sum 
score, FI-2 % 
50 
(27–92)8
51 
(28–94)7
42 
(22–81)1
0.29 57 
(33–99)2 
39  
(21–71)6
0.01
Hip flexion 
endurance sum 
score, FI-2 %
40 
(25–79)11
40 
(25–91)9
42 
(24–61)2
0.49 48 
(28–100)2 
35  
(20–70)8
0.01
TST, Sec 21 
(17–27)24
21 
(17–26)18
23 
(18–29)6
0.59 19 
(16–25)13 
25  
(18–30)9
0.001
Values are presented as median (IQR). lcSSc: limited cutaneous SSc; dcSSc: diffuse cutaneous 
SSc; No–mild lung disease: Medsger disease severity score 0–1; Moderate–end-stage lung disease: 
Medsger disease severity score 2–4; FI-2%: % of predicted Functional Index-2; TST: Timed-Stands 
Test (in seconds); n=missing numbers. Due to missing data, in diffusing capacity of the lung for 
 carbon monoxide and/or forced vital capacity, 7 patients could not be classified as having no–mild 
or moderate–end-stage lung disease. 
Figure 3 B. Muscle endurance in hip flexion in right side in patients with systemic  sclerosis 
(SSc) and reference group divided in different age groups. The values for hip flexion muscle 
endurance % of predicted according to Functional Index 2 in median. * p<0.05, **p<0.01, 
***p<0.001.
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Patients with SSc had lower shoulder-arm AROM in both right (p=0.003) and left 
(p=0.001) compared with reference values (Table 8). A difference in sum score 
was found between patients with lcSSc 57 (52–60) and dcSSc 53 (48–57) where 
those with dcSSc had more impaired AROM (p=0.003). No differences were found 
between patients with no–mild and moderate–end-stage lung disease.
Table 8. Functional Shoulder Assessment (FSA) in patients with systemic sclerosis 
(SSc) and reference group stratified by different age groups.
FSA, right, 
4–24 points
p-value FSA, left, 
4–24 points
p-value
All age 
groups
SSc (n=205)
Reference group B (n=246)
22 (20–24)2 
23 (22–24)3
0.003 23 (20–24)2
23 (22–24)3
0.001
Ages ≤49 SSc (n=44)
Reference group B (n=41)
22 (20–24)2
23 (22–24)2
0.42 24 (22–24)2
24 (23–24)
0.12
Ages 50–59 SSc (n=58)
Reference group B (n=23)
23 (21–24)
23 (23–24)
0.26 23 (21–24)
23 (23–24)
0.28
Ages 60–69 SSc (n=54)
Reference group B (n=74)
22 (19–24) 
23 (23–23)2
0.002 23 (20–24) 
23 (23–24)3
0.008
Ages ≥70 SSc (n=49)
Reference group B (n=108)
21 (20–23)
22 (21–23)1
0.001 21 (19–23)
23 (21–24)
<0.001
FSA: Functional Shoulder Assessment (4–24 points for the four included tasks: hand-raising, 
hand-to-opposite-shoulder, hand-behind-back and hand-to-neck); The values for FSA are pre-
sented as points; n=missing numbers. Reference group B is collected from [110]. 
Table 7. Timed-Stands Test (TST) in patients with systemic sclerosis (SSc) stratified by 
subgroups defined by skin involvement (limited or diffuse SSc) and extent of lung disease 
(no–mild or moderate–end-stage) in comparison with predicted reference values. 
TST, Seconds Predicted reference 
values TST, Seconds
p-value
All patients (n=205) 21 (17–27)24 17 (15–18) <0.001
LcSSc (n=169) 21 (17–26)18 17 (16–18) <0.001
DcSSc (n=36) 25 (18–29)6 17 (14–18) <0.001
No–mild (n=116) 19 (16–25)13 17 (15–18) <0.001
Moderate–end-stage (n=82) 25 (18–30)9 17 (16–18) <0.001
Values are presented as median (IQR). LcSSc: limited cutaneous SSc; dcSSc: Diffuse cutaneous 
SSc; No–mild lung disease: Medsger disease severity score 0–1; Moderate–end-stage lung disease: 
Medsger disease severity score 2–4; n=missing numbers. Due to missing data, in diffusing  capacity 
of the lung for carbon monoxide and/or forced vital capacity, 7 patients could not be classified as 
 having no–mild or moderate–end-stage lung disease.
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5.3 Paper III: Experiences of physical activity 
and exercise
From informant’s voiced experiences three themes emerged; Essential for life 
and health, Disease-related and other hindrances, and, Own understanding 
about PA/exercise and support from healthcare. Eight categories were identi-
fied. Themes and categories are presented in Figure 4. 
The first theme, Essential for life and health, consisted of three categories; 
Diminishes symptoms and is as effective as pharmaceuticals, Reduces fear of 
deterioration, and, Feeling healthy and satisfied with oneself. 
In the category Diminishes symptoms and is as effective as pharmaceuticals it was 
expressed that PA/exercise was preferred as treatment instead of pharmaceuticals, 
mainly due to the positive effects on both physical and mental well-being. Especially 
improved blood circulation after PA/exercise was highlighted as an important result 
even though it was also voiced that the blood circulation initially could get worse 
during PA/exercise. Additionally, there were no severe side effects of PA/exercise 
even though pharmaceuticals sometimes were needed to treat disease symptoms. 
Figure 4. Physical activity (PA) and exercise and the connection to the three Themes (oval 
shapes) and their categories. Bold arrows between central triangle and ovals indicate 
 suggested mutual relationship.
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Presented examples of quotes are followed by the informants’ specific identifica-
tion code, i.e. I-I, no–mild lung disease (Informant I which has SSc with no–mild 
lung disease).
– As soon as one starts to work [spinning class] and get the circulation 
working, it takes a few minutes, but then it speeds up and it sort of remains 
until at least the next day, every so often two days (I-I, no–mild lung disease)
– I don’t want to take…medication. Somehow, I have a vision that I must get 
starting, more and better, with my exercise in order to, maybe sometime in 
the future, need not to take the medication (I-M, no–mild lung disease)
Fear of worsening was an incentive to start, or continue, PA/exercise as expressed 
in the category Reduces fear of deterioration. The improved aerobic capacity and 
muscle strength after PA/exercise led to an increased sense of safety and it helped 
to reduced fear of deterioration. A need to maintain regular physical activities to 
have a long life worth living, and to be able to continue doing activities were rec-
ognised as motivating for PA/exercise.
– The more exercise I get, the better my health and bigger opportunities to 
survive longer. I don’t want die. It’s now that my life has started, somehow 
(I-O, moderate–end-stage lung disease)
In the category Feeling healthy and satisfied with oneself it was expressed that 
PA/exercise installed both a physical and emotional state of healthiness and well-
ness, which gave a sense of being alive. Feelings of increased belief in oneself 
and increased self-esteem were phrased after PA/exercise, even when experienc-
ing severe breathlessness. Muscle soreness was also experienced as something 
positive as it both was a proof that the exercises had paid off and that it diverted 
focus from other disease-related pain. 
– You feel, you get a diagnosis, that means you get labelled as sick. But 
when you exercise you don’t notice it, instead you feel healthier, when you 
have exercised, and everything worked out fine (I-L, no–mild lung disease) 
– Interviewer: What is the strongest feeling of physical activity that you can 
think of? Oh, you feel healthy. That’s the best, …Yes, I think so, strong, vital, 
you can do more, enjoys life (I-N, moderate–end-stage lung disease)
The second theme, Disease-related and other hindrances, consisted of three 
categories; Breathlessness, pain and other disease consequences limit, Risk of 
worsening, and, Non-disease barriers.
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In the first category Breathlessness, pain and other disease consequences limit, 
typical and expected disease-related symptoms and problems were stated. 
Breathlessness, pain of various origin, and tight skin as well as tiredness were 
experienced as both barriers to, and consequences from PA/exercise. 
– But it’s the breathing that limits me the most [at PA] (I-F, moderate–end-
stage lung disease)
– Sometimes I think, if I hadn’t these troubles [pain] with the feet...I would 
do much more, I would run, I would walk, and I would do so much more 
than I do today (I-B, no–mild lung disease) 
In the Risk of worsening expressions about negative consequences from PA/exer-
cise were voiced. Shortness of breath was perceived as frightening and too high 
intensity exercise could cause, and worsen, symptoms like pain and digital ulcers. 
– Sometimes I go all in [exercise] and that leads to [severe] muscle  soreness, 
in scleroderma that is terribly painful (I-O, moderate–end-stage lung disease)
– It’s almost as if I’m counting how long they [hands] are white [when 
Nordic walking] because I’ll think, please don’t become digital ulcers now… 
because they are painful (I-H, no–mild lung disease)
Non-disease barriers such as lack of time and lack of motivation as well as 
cold weather, not only outdoors, were experienced as barriers to PA/exercise. 
Furthermore, distance to and access to parking lots could make accessibility 
to health-care providers and gyms more difficult. Financial aspects like travel 
expenses and fees when visiting the physiotherapist were considered as barriers. 
– When life is fully scheduled, should I do as the others and ask to be 
 partially on sick-leave and maybe take care of my health and that maybe 
isn’t such a bad idea but… I’m not there today (I-E, moderate–end-stage 
lung disease)
– [Barriers] When it comes down to systemic sclerosis I think more support 
to exercises, from the government, more money to training sessions with the 
physiotherapist or to gyms (I-N, moderate–end-stage lung disease)
The third and final theme, Own understanding about PA/exercise and support 
from healthcare, consisted of two categories; Experience-based knowledge about 
own capability and PA/exercise, and, Education and support from healthcare and 
others. 
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In Experience-based knowledge about own capability and PA/exercise, it was 
expressed that knowledge about own physical limitations, as well as experience of 
muscle strengthening exercises were beneficial as it both made exercising easier 
and reduced the risk of self-inflicted injury. By making adaptations to intensity, 
by exercising indoors when cold outside, or biking instead of running, and, using 
protective gloves or special soles in the shoes, made PA/exercise easier even when 
having a more severe form of SSc. Also, the need of analgesics or supplemental 
oxygen was highlighted as it sometimes made PA/exercise possible to perform. 
– I don’t run anymore, because the time it takes, to warm-up and get the 
 circulation starting, during this time I get Raynaud…when it’s this cold out-
side, and that’s not good. So now one has to walk and run on a treadmill or 
bike on a spinning-bike instead of going outside (I-I, no–mild lung disease)
– But you need four liters [supplemental oxygen] when you move around? 
Yes, five and a half when I’m sitting and doing my exercises. Interviewer: 
And you can feel exactly how much you need? Oh, yes (I-D, moderate–
end-stage lung disease)
In the category Education and support from healthcare and other informants it 
was expressed that information and support from physiotherapists was beneficial. 
Both general information and specific advices were appreciated even if not all 
expressed that they had received, needed or wanted information or support about 
PA/exercise. Support from other, like friend and family, and phone applications, 
also facilitated PA/exercise. 
– The physiotherapy kick-start me into exercising when I’ve fallen behind. 
Then I go there for like three weeks, and this get me started… It makes me 
happy (I-O, moderate–end-stage lung disease)
– [Not received information about the benefits of exercise in SSc] …I like to 
read about these processes in the blood vessels. It’s quite complicated…, but 
when you read through it you understand that you can improve, a small part 
of it by exercise. So, I have done it anyway (I-I, no–mild lung disease)
5.4 Paper IV: Health-related quality of life
Patients with SSc had lower HRQoL, in all eight domains of the SF-36, when 
compared with age- and gender-matched reference values (Figure 5). Both PCS 
and MCS were lower than reference values (p<0.001). Patients with no–mild 
(p<0.01–0.001) and moderate–end-stage lung disease (p<0.001) had lower scores 
than their respective reference values (Figure 5), likewise did both groups have lower 
PCS (p<0.05–0.001) and MCS (p<0.001) than their respective reference values. 
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Patients with no–mild lung disease had better HRQoL than patients with moder-
ate–end-stage lung disease (p<0.05-<0.001) except for the mental health (Figure 5), 
and the PCS was higher (p<0.001), but no differences were found in the MCS 
between the groups (p=0.2). 
Self-reported anxiety did not differ between groups but depressive symptoms, as 
measured with HAD, were higher, 4 (2-7), in the group with moderate–end-stage 
lung disease, compared with 3 (1-7) in no–mild (p<0.05).
Figure 5. Radar chart of the eight dimensions of Medical Outcomes Study 36-Item Short 
Form Health Survey (SF-36) in Swedish general population, 279 patients with systemic 
sclerosis (SSc), 156 SSc-patients with no–mild and 115 with moderate–end-stage lung 
disease. The age-and gender matched reference values are from the general Swedish 
population [112]. In each area the scores range from 0 (worst) to 100 (best). Significant 
differences were found between all patients with SSc and their controls in all domains 
(p<0.001), as well as between patients with no–mild and with those with moderate–end-
stage lung disease (p<0.0001 – 0.036) except in the mental health domain (p=0.12).
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The total sample of patients with SSc had relatively low disability-scores, 0.38, as 
measured with the HAQ-DI. Highest disease-specific disability on the VAS was 
RP, 44 mm, followed by General, 29 mm, Pain, 23 mm, and both Dyspnoea and 
Gastrointestinal, 12 mm and last digital ulcers, 2 mm. 
Patients with no–mild lung disease had HAQ-DI 0.38 whereas moderate–end-
stage had 0.63 (p<0.001). Patients with moderate–end-stage lung disease had more 
problems on VAS General (p<0.001) and VAS dyspnoea (p<0.001) than patients 
with no–mild lung disease (Table 9).
Table 9. Disability in patients with systemic sclerosis as defined by lung disease 
(no–mild or moderate–end-stage).
No–mild lung  
disease (n=156)
Moderate–end-stage 
lung disease (n=115)
p-value
HAQ-DI (0-3 points) 0.38 (0-0.78)2 0.63 (0.13-1.38)2 0.001
    VAS-General 21 (8-46)11 38 (20-56)8 <0.0001
    VAS-Dyspnoea 3 (0-26)8 31 (7-72)6 <0.0001
    VAS-RP 42 (15-77)8 48 (16-74)6 0.97
    VAS-Digital ulcers 2 (0-16)14 4 (0-21)10 0.28
    VAS-Pain 20 (1-48) 30 (4-54)1 0.14
    VAS-Gastrointestinal 8 (0-50)25 21 (2-59)27 0.09
Values presented as median (IQR). HAQ-DI: Health Assessment Questionnaire Disability Index; 
VAS: visual analogue scale, 0-100 mm; RP: Raynaud’s phenomenon; n=missing numbers. 
Only 30% of the patients with SSc reported they had been PA on a low-moderate 
intensity the past six months on 6-7 days/week. More patients with no–mild lung 
disease (34%) than moderate–end-stage (24%) reported they were PA on a low-
moderate intensity (p<0.05).
More than half, 52%, of patients with SSc reported that they never or irregularly 
had exercised the past year, and, 22% had exercised ≥3times/week. More patients 
with moderate–end-stage lung disease (60%) never or irregularly exercised in 
contrast to patients with no–mild (45%) (p<0.05), there were also fewer patients 
with moderate–end-stage lung disease that exercised ≥3times/week (15%) than 
in the group with no–mild (28%) (p<0.05). 
A difference in self-reported physical capacity was found overall between patients 
with no–mild lung disease and moderate–end-stage (p<0.001) (Figure 6). 
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As expected, there was a strong correlation between SF-36 PCS and HAQ-DI, 
moderate correlations between SF-36 PCS and self-reported physical capacity, VAS 
General, VAS Pain, and VAS Dyspnoea. There were low correlations between PCS 
and arthritis/arthralgia, the Medsger disease damage for lung, HADd, DLCO%, 
FVC% and VAS Gastrointestinal. 
The SF-36 MCS correlated moderately with both HADa and HADd, low with VAS 
General, VAS Dyspnoea and VAS Pain. 
Correlations between SF-36 PCS, MCS and variables of interest, in the two sub-
groups based on lung disease, are presented in Table 10. 
Figure 6. Self-reported physical capacity in patients with systemic sclerosis divided into 
no–mild and moderate–end-stage lung disease. Significant differences between groups 
were revealed in walking ≤ 500 meters (p<0.001) and jog-running (p=0.002). 
 
**
***
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Table 10. Correlations between the composite scores from SF-36 (Physical Component 
Score and Mental Component Score) with clinical characteristics and disability. 
 No–mild lung disease  
(n=156)
Moderate–end-stage  
lung disease (n=115)
 PCS  MCS  PCS  MCS
Arthritis/Arthralgia (%)  -0.46 ***  -0.22**  -0.29 **  0.03
Medsger disease damage
     Heart  -0.11  -0.02  -0.26 **  0.04
HAQ-DI  -0.70 **  -0.23 **  -0.70 **  -0.13
     VAS-General  -0.49 **  -0.49 **  -0.47 **  -0.36 **
     VAS-Dyspnoea  -0.53 *  -0.26 **  -0.34 **  -0.24 **
     VAS-RP  -0.01  -0.17 *  -0.33 **  -0.03
     VAS-Pain  -0.52 *  -0.23 **  -0.49 **  -0.19 *
     VAS-Gastrointestinal  -0.24 **  -0.24 **  -0.32 **  -0.17
Self-reported physical capacity, overall  0.51 **  -0.18 *  0.55 **  0.03
HADa  -0.15  -0.62 **  0.02  -0.57 **
HADd  -0.37 **  -0.64 **  -0.25  -0.62 **
SF-36: Medical Outcome Study Short-Form 36; PCS: physical component score; MCS:  mental 
component score; HAQ-DI: Health Assessment Questionnaire Disability Index; VAS: visual 
analogue scale 0-100 mm; RP: Raynaud’s phenomenon; HADa/HADd, Hospital Anxiety and 
Depression scale, subitem anxiety and depression. Spearman´s correlation coefficients inter-
pretation: 0.00-0.25: little if any; 0.26-0.49: low; 0.5-0.69: moderate; 0.7-0.89: high; 0.9-1: very 
high; bold numbers indicate results ≥0.26; * p<0.05, ** p<0.01, *** p<0.001.
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6 DISCUSSION
6.1 Main findings
The overarching aim of this Thesis was to increase the knowledge of physical 
function, physical activity, and quality of life in patients with SSc with different 
degrees of lung disease. Even though patients with SSc did report lower physical 
capacity and more limiting factors for PA as well as that it was more common 
among the patients to report that they “never exercised” compared to age- and 
gender-matched controls, no differences were seen in self-reported PA nor time 
spent sitting, regardless of lung disease (Paper I). Patients with SSc had a markedly 
reduced muscle endurance in upper and lower extremities, and a reduced muscle 
strength in the lower extremities. Patients also had a somewhat impaired AROM 
in the shoulder-arms, especially patients older than 60 years. Patients with dcSSc 
had more impaired AROM in the shoulder-arms than lcSSc. There were no differ-
ences in muscle function between patients with lcSSc and dcSSc but patients with 
moderate–end-stage lung disease had less muscle endurance in both shoulder- and 
hip flexion as well as lower muscle strength in the lower extremities than patients 
with no–mild lung disease (Paper II). In Paper III informants with SSc experi-
enced that PA/exercise was essential for life and health and that it reduced fear of 
deterioration, and, installed a feeling of health and satisfaction. Disease-related 
and other hindrances like shortness of breath and pain were problematic. An own 
understanding about PA/exercise, and support from healthcare was facilitating. 
Further it was expressed that information/education and support was both needed 
and beneficial. In Paper IV we showed that patients with SSc overall had a low 
HRQoL. Patients with moderate–end-stage lung disease had lower HRQoL and 
physical capacity as well as more depressive symptoms, disabilities and disease 
damage than patients with no–mild lung disease. Patients with moderate–end-stage 
lung disease were also less PA and exercised less. 
6.2 Physical activity and exercise
In Paper I, self-reported PA/exercise were assessed and found to be lower than in 
age- and gender-matched population-based controls. Patients with moderate–end-
stage lung disease reported lower levels of PA/exercise than those with no–mild 
lung disease in Paper IV. 
The reported levels of PA on a low-moderate intensity 6-7 days/week the past six 
months are low among patients with SSc (Paper I). Unfortunately, even fewer 
patients in the group with moderate–end-stage lung disease reported that they were 
PA on low-moderate intensity 6-7 days/week the past six months (Paper IV). Similar 
indications of less regular exercise were seen in both groups, with the exception 
in patients with no–mild lung disease where slightly more patients reported that 
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they exercised ≥3 times/week. However, it is encouraging to see, in Paper IV, that 
more patients in both groups report they have a physical capacity allowing them to 
jog-run. These differences may be explained by the fact that during the recent years 
of inclusion of patients into the research SSc-cohort at Karolinska, several patients 
have been diagnosed quite early after symptom onset, and thus probably have less 
overall disease damage. The higher levels of self-reported physical capacity are 
encouraging and may reflect a shift in knowledge among the general population, as 
well as among patients with rheumatic diseases, in that exercise is beneficial. This 
hypothesis is supported by voiced expressions in Paper III, where it was expressed 
that PA/exercise could prolong their lives. It was also expressed that physical abilities 
had to be maintained or they would be lost. Feelings of inquietude were expressed 
when being inactive whereas senses of joy, increased self-esteem and increased 
health- and wellness were experienced after PA/exercise. 
6.3 Patients experiences of physical activity and exercise
According to the shifting perspectives model of chronic illness [117], living with a 
chronic illness is an ongoing, continually shifting process in which people experi-
ence a complex dialectic between themselves and their “world”. The perspective of 
chronic illness determines how individuals/patients react to the disease, themselves, 
healthcare professionals as well as in situations that are affected by the illness, 
like social interactions and work. It is the perception of reality that is the kernel of 
how individuals/patients interpret, and respond, to their illness [117]. This shifting 
between putting the illness, or the wellness, in the foreground are different perspec-
tives on how one may change in perception. Often do newly diagnosed persons have 
an illness perspective that has a utilitarian, or protective, function. The perspective 
of having wellness in the forefront is said to be using the illness as an opportunity 
to have a meaningful change in the relations and interactions with others. As seen 
in some of the phrased experiences in Paper III, as in the theme Reduces fear of 
deterioration, as well as in Feeling healthy and satisfied with oneself, the per-
spective of having the wellness in the foreground seems to be the most common 
approach to the disease, at least in this small group of patients with SSc. 
Physical inactivity and sedentarism are central problems in patients with COPD 
where inactivity is reported to play a crucial role in the development of co-morbidities 
[118]. Regardless of disease severity, a sedentary lifestyle is present in all stages of 
COPD, and worsens as the disease severity progresses [118]. Problems with inactivity 
have previously been presented in patients with SSc [66]. As previously mentioned, 
the aims of rehabilitation in rheumatic diseases are, beside control of inflammatory 
processes and prevention of further disease damage, to maintain physical function 
and participation in society [74]. As in pharmacological treatment the rehabilitation 
process needs to start early after disease onset, be individualized and needs-driven. 
Furthermore, interventions and agreements between healthcare professionals and 
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patients’ need to be followed up, evaluated and continue as long as the demand 
remains. These statements are echoed in Paper III where information/support from 
physiotherapists was considered as beneficial, especially early after disease-onset. 
Likewise, a need of individualized information about PA/exercise were sought 
after. The possibility to meet the physiotherapist when needed gave a noticeable 
boost, a kick-start, when having fallen behind. These expressions are coinciding 
with the statements in MoRR, that rehabilitation ought to include also PA/exercise 
that are adapted to the patient’s needs. Likewise, help with pain/tiredness/anxiety/
depression symptoms and problems with sleep [74].
Fatigue has previously been reported to be a major problem in SSc [52,119]. In 
Paper III the informants did not express themselves as having problems with 
fatigue, instead they used wordings like tired and tiredness. As no question in the 
interview guide was formulated to gain deeper insight into this problem the pos-
sible influence of fatigue on PA/exercise could not be explored. 
6.4 Physical function
Paper II includes as far as we know the largest structured assessments of muscle 
endurance, muscle strength and AROM by use of FI-2, TST and FSA, done in 
patients with SSc. 
Others have recently shown significantly lower extremity isokinetic muscle strength 
compared to healthy controls [120]. The FI-2 was used to measure dynamic 
repetitive muscle endurance in two muscle groups, shoulder- and hip flexion. 
The notably low muscle endurance, regardless disease subphenotype or degree of 
lung disease, clearly represent a major problem for most patients with this chronic 
disease. In myositis comparable, low levels of FI-2 shoulder- and hip flexion have 
recently been presented [121]. In another study, on patients with newly diagnosed 
 myositis, the muscle endurance was lower than in our patients with SSc. The FI-2 
was able to detect both worsening and improvements in muscle endurance at six 
and 12 months after diagnosis [122]. Among patients with ILD adaptations to 
a sedentary lifestyle is common behaviour, which in turn leads to a detrimental 
effect on muscle function. Not only is respiratory muscle function impaired, but 
also lower extremity muscle strength is reduced, especially in the quadriceps 
[123]. In patients with advanced ILD significantly worse muscle strength in the 
lower extremities, and worse results on functional muscle tests like the Timed Up 
and Go in comparison with healthy controls, have been presented. However, no 
differences were seen in the arms [124]. This is similar to our findings, in where 
patients needed significantly longer time to complete the TST, especially in the 
group with moderate–end-stage lung disease, where 60% of the patients had lung 
fibrosis. Furthermore, in Paper II we also noticed that our patients with SSc only 
had a muscle endurance of 40 % of predicted values in the hip flexion but 50 % 
in shoulder flexion.
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6.5 Health-related quality of life
As previously shown, HRQoL is reduced in patients with SSc [59]. Furthermore, 
patients with SSc seems to have lower SF-36 scores in several of the domains in 
comparison with other chronic ailments like heart disease, hypertension and dia-
betes and also depression [125]. In Paper IV we showed that patients with mod-
erate–end-stage lung disease had lower HRQoL than those with no–mild which 
is not surprising as they also have more disease damage, longer disease duration 
and reported lower physical capacity than patients with no–mild lung disease. 
Earlier studies have shown that patients with dcSSc have more severe disease 
manifestations [1], similar to our findings in the patients with moderate–end-
stage lung disease. The PCS in our cohort with moderate–end-stage lung disease 
was similar with patients with SSc and PAH in another study [126], where they 
also found high correlations between a dyspnoea questionnaire and SF-36 PCS. 
Likewise, another study reported that the FVC is a significant independent pre-
dictor of disability/function (HAQ) and physical HRQoL [127]. Interestingly, we 
found higher associations between VAS dyspnoea and the PCS in patients with 
no–mild lung disease than in the group with moderate–end-stage. This could be 
due to that patients with no–mild lung disease had a shorter disease duration and 
that they found dyspnoea as an ominous symptom that can indicate a worsening 
of the disease and something that might hinder an active life style. Another way 
to look at this is that patients with moderate–end-stage lung disease have several 
other disease-related issues, like RP or gastrointestinal problems hindering PA, and 
that they have adapted to a sedentary lifestyle, and therefore dyspnoea is a lesser 
problem. In Paper III it was expressed that limited ability to breath was frightening. 
Breathlessness, pain and other disease consequences limit PA/exercise. An earlier 
study have also found that disease-related problems like tiredness interfering with 
life, pain and deformed hands makes ADL more difficult [128]. Deformed hands 
because of SSc naturally affect the possibilities to function adequately in ADL and 
this is shown in the HAQ-DI which was higher (more disability) among patients 
with moderate–end-stage lung disease, even though both patient groups had the 
same, high, correlation between HAQ-DI and PCS as seen in Paper IV. Here we 
only focused on differences in self-reported disability/function among patients 
with different degrees of lung involvement and not on cutaneous subphenotypes. 
6.6 Scoring of lung disease severity
The use of the Medsger disease severity score has not previously been used as a 
dichotomous variable to categorize lung disease in patients with SSc. The rea-
son we chose this way to divide patients with different degrees of lung disease is 
mainly because it provides an, overall, simple and clear distinction between sub-
clinical and clinical cardiopulmonary symptoms. We hypothesized that it would 
be possible to distinguish patients with different degrees of lung involvement by 
this classification. Others have proposed different cut-offs based on lung disease. 
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Goh et al. [31] proposed a method based on findings from HRCT and FVC, with 
70% as cut-off for staging ILD into limited or extensive disease. This method 
may be of use in patients with ILD only, but less feasible in patients with SSc 
that also can have reduced DLCO% and/or PAH. In the Scleroderma Lung study 
[61] which studied patients with SSc with active alveolitis, another approach was 
used. In this study the values for FVC% and DLCO% were divided into mild 
(>70% of predicted), moderate (50-70%), and severe (<50%), however, due to 
low number of eligible patients in the severe FVC group, severe and moderate 
groups were combined for analysis. For some reason, also groups with mild and 
moderate DLCO were combined. 
In papers I, II and IV we found that the dichotomization of the Medsger disease 
severity score for the lung has been able to discriminate between patients with no–
mild and moderate–end-stage lung disease as to both objective and self-reported 
variables. 
In Paper I we used the term moderate–severe lung disease for all patients that had 
a disease damage score of 2, 3, and 4. In papers II-IV we changed to moderate–end-
stage as we considered this to be a more correct way to describe the total variation 
in lung disease in our cohort. 
6.7 Methodological considerations
In this Thesis both quantitative and qualitative methods were used to answer the 
research questions. Different statistical methods were therefore used. Most of the 
variables were non-normally distributed which prompted the use of non-parametric 
tests but to be able to compare our results with previous research we have calcu-
lated, and presented part of the results, by use of parametric statistical methods. 
For example, in Paper IV we used parametric presentation for result of SF-36. 
However, we did also use non-parametric methods to confirm our findings without 
relevant discrepancies between the two different approaches. 
Considering the rarity of SSc the large sample sizes are a methodological strength, 
especially in Paper II and Paper IV. In Paper I the large cohort with patients with 
SSc and the well-matched population-based controls are the strengths of this study. 
On the other hand, we used self-reported questions and recall errors are common 
when reporting habitual activities on light to moderate intensity, like house-work 
and walking [129]. These types of activities are often under-reported which might 
be the case in our study. Self-reported data may not be as valid or reliable as data 
gathered by for example accelerometers used in a few studies in SSc [66,67]. 
Conversely, an accelerometer does not take into account if the participant is carry-
ing bags and/or walks in stairs which naturally is more strenuous than just walking 
[130]. Several studies [101,131] have shown that objectively measured physical 
activities produced a different activity pattern and lower values in comparison 
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with frequently used self-reported questionnaires. These studies [101,131] had 
a relatively large dropout and it is likely that the individuals who completed the 
test were the most fit and/or motivated, alternatively that some participants had 
difficulties with handling the devices. Our study, on the contrary, had a very high 
response rate, >90% among patients in the SSc group and 98% in the control group 
which probably is because all participants were summoned to a visit at the clinic. 
In Paper II, the relatively large number of missing data in the TST is a drawback. 
The reason for this problem is due to several factors: not all patients could com-
plete the ten full stands because of weakness or were stopped because of incorrect 
performance such as using their hands to push up or to maintain balance. Others 
ended the test prematurely because of pain in hips and/or knees or because of severe 
dyspnoea. The 30-second sit-to-stand test [88] may be a more suitable test in future 
assessments, or clinical trials, as even if the test person only manages to complete 
a couple of repetitions it is still a valid result, whereas if the test person is not able 
to complete the ten full stands in TST no result is acquired. 
In Paper III individual interviews were performed. Other researchers in SSc have 
used focus group discussions when investigating coping strategies among patients 
with SSc [132-134]. This approach let the researcher gather many individuals and 
take part of their experiences [135]. However, as SSc is such a rare and heterogenous 
disease we chose to do individual interviews in order to let the informants freely 
express their experiences. Also, it increased the anonymity of the informants. We 
believe this enhanced informants’ ability to easily express their thoughts, beliefs 
and experiences without risk feeling subdued by others that may have been more 
vocal [105]. On the other hand, being part of a focus group can help to facilitate 
discussion among the informants, ease recollection of details and it can also help 
to characterise both divergent and common experiences [105].
One of the differences between standard calculations used in quantitative research 
and qualitative research is that qualitative research to a higher extent is dependent 
on skills and experiences among the researchers in the analysis of data [105]. To 
increase the trustworthiness of the analysis triangulation was done between the 
first Author and two senior researchers with experience of qualitative methodol-
ogy. Discussion and confirmation of the findings were also done with the other co-
authors as well as in a research group with experiences of both qualitative research 
and clinical care within the field of rheumatology. We find the results plausible 
but are aware that other researchers may discover, and interpret, other findings in 
the transcripts, but the content would still be the same. The transferability of our 
findings is to some extent dependent on other readers’ experiences and contexts. 
We think that the diversity among our informants increases the trustworthiness of 
our findings.
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In qualitative research the sample size depends on the richness in information 
gathered from the informants and the variety in the sample [108]. In paper III 16 
interviews were conducted which we considered sufficient to achieve an adequate 
and plausible representation of experiences of PA/exercise in SSc. The strategic 
identification of informants is a strength as informants represented both women 
and men in various age, and with various diagnosis duration, lung involvement 
and disability. However, it is still possible that by performing additional interviews 
new information could be presented [104].
Among the individuals that were interviewed some were not native Swedish. 
We believe it to be a strength to have the possibility to include participants from 
other settings and cultural backgrounds even though there to some extent may be 
a language barrier. Similar language-related problems did occur in Paper IV where 
some patients were unable to answer the questionnaires and therefore could not 
be included in the study. 
Regression analysis would have strengthened the results In Paper IV. We only used 
a method to quantify the relationship between variables. To be able to determine the 
strength, and direction, of the association between HRQoL and independent vari-
ables (e.g. Medsger disease damage, HAQ-DI, gender, age and physical capacity), 
we plan to perform regression analysis. 
6.8 Concluding remarks and future perspectives
This Thesis has demonstrated that patients with SSc “never exercise” to a higher 
extent than population-based controls but overall, they were not less physically 
active than population-based controls. However, most patients do not reach the 
World Health Organization´s recommendations of physical activity (150 minutes 
of moderate-intensity aerobic physical activity throughout the week, or, do at least 
75 minutes of vigorous-intensity aerobic physical activity throughout the week, 
or, an equivalent combination of moderate- and vigorous-intensity activity) [136]. 
Furthermore, the results showed that self-reported physical capacity were lower 
among patients with SSc compared to population-based population, and they have 
markedly low muscle strength and muscle endurance compared to reference val-
ues. Patients with moderate–end-stage lung disease also have lower self-reported 
physical capacity and more impairments in muscle strength and muscle endurance 
than those with no–mild lung disease, but surprisingly no differences were found 
between patients with lcSSc and dcSSc. Patients with SSc, including patients 
with both no–mild and moderate–end-stage lung disease experience PA/exercise 
as essential for life and health. There are different disease-related and other hin-
drances, but own understanding about PA/exercise and support from healthcare 
facilitated the possibilities to be physically active and exercise. Patients with 
moderate–end-stage lung disease have lower self-reported physical capacity, are 
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less PA/exercise, are more disabled, have a lower HRQoL and have more depres-
sion symptoms than patients with no–mild lung disease. The studies in this Thesis 
have contributed with new knowledge about how to develop future PA/exercise 
programs for patients with SSc, especially for those with more severe lung disease. 
The Thesis also shows the need of rheumatological rehabilitation for patients with 
SSc with focus on physical function, physical activity and exercise and HRQoL.
6.8.1 Conclusions Papers I – IV
In Paper I we conclude that even though patients with SSc reported lower physi-
cal capacity and more limiting factors for physical capacity, and more patients 
reported they “never exercised”, than age- and gender-matched population-based 
controls, no differences in self-reported physical activity nor time spent sitting 
were found. Further development of physical activity programmes for patients 
with SSc, and especially for those patients that never exercise, or have physical 
impairments is needed. 
In Paper II we drew the conclusion that patients with SSc have markedly reduced 
muscle endurance in both the upper and lower extremities, reduced muscle strength 
in the lower extremities, as well as an impaired AROM in the shoulder-arm  girdles. 
Patients with moderate–end-stage lung disease had more impaired muscle endur-
ance and strength than patients with no–mild lung disease but no differences were 
found between lcSSc and dcSSc. Not only muscle strength, but also dynamic 
muscle endurance needs to be measured in patients with SSc.
In Paper III we found that patients with SSc experienced that PA/exercise was 
essential for life and health. PA/exercise reduces fear of deterioration, but it was 
also expressed as a risk of worsening. Furthermore, disease-related and other hin-
drances like shortness of breath and pain were problematic. An own understand-
ing about PA/exercise, and support from healthcare was facilitating. It was also 
expressed that information/education and support was both needed and beneficial. 
These findings add new knowledge to the effects of PA/exercise in SSc and what 
is perceived as facilitating and hindrances.
In Paper IV we conclude that patients with SSc and moderate–end-stage lung 
disease have a lower physical HRQoL, more depression symptoms, are more 
disabled, and additionally they have more overall disease manifestations. Patients 
with moderate–end-stage lung disease have also a lower physical capacity, are less 
PA and they exercise less than patients with no–mild lung disease.
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6.8.2 Future research
Due to the rarity of SSc, planning and performing a multi-centre exercise approach 
would be of great value. The optimal way of exercising with the aim to increase 
both muscular strength and muscular endurance in patients with different degrees 
of lung disease needs to be further elucidated, especially in patients with moder-
ate–end-stage lung disease. 
Patients in the interview study expressed that physical exercise could increase 
blood circulation but whether positive long-term effects on blood circulation are 
achievable after PA/exercise needs to be further investigated, preferably in a ran-
domized controlled trial. Possible outcome measures could be muscle biopsies 
and/or Power Doppler ultrasound to evaluate changes in capillary density, and, 
blood circulation. 
The impact of pain and fatigue on PA/exercise, and vice versa, also needs to be 
further investigated. It would also be interesting to further study how pain and 
fatigue is associated with different degrees of lung involvement, preferably with 
a qualitative approach.
Likewise, it would also be of interest to investigate if disability/function, HRQoL 
and anxiety/depression symptoms can be altered after participating in PA/exercise 
intervention, and what long-lasting effects can be gained in self-reported HRQoL, 
especially in patients with moderate–end-stage lung disease.
How the muscle strength and muscle endurance changes over time in SSc needs 
to be studied in a longitudinal study. 
In parallel with the above efforts, a further development of the Swedish Rheumatology 
Quality register (SRQ) SSc module would be important. A combination of high-
quality objective, and self-reported longitudinal, data would enhance the ability 
to understand long-term outcomes in SSc and to evaluate the results of current 
pharmacological as well as non-pharmacological treatments.
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